Results 71 to 80 of about 5,123 (202)
eJHaem, Volume 6, Issue 4, August 2025.ABSTRACT Background Anaemia significantly affects health outcomes and quality of life. While blood transfusion remains a common intervention, alternative treatments, such as iron supplementation and erythropoiesis‐stimulating agents (ESAs), offer potential to mitigate transfusion‐associated costs.
Hiro Farabi +9 more
wiley +1 more source
DETERMINATION OF DARBEPOETIN ALFA IN RABBIT PLASMA BY ELISA
Разработка и регистрация лекарственных средств, 2019 Method of quantitative determination of darbepoetin alfa in rabbit blood plasma was developed. Quantitative determination was performed by ELISA using commercially available ELISA kits for assay «Erythropoietin ELISA-Best».
M. V. Karlina +5 more
doaj
How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome
British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley +1 more source
Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study
BMC Nephrology, 2011 Background Macrocytosis occurs in chronic hemodialysis (CHD) patients; however, its significance is unknown. The purpose of this study was to establish the prevalence and distribution of macrocytosis, to identify its clinical associations and to ...
West Kenneth A +3 more
doaj +1 more source
Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke: review of literature [PDF]
, 2017 The article contains the analysis of medical and biological publications from the global database created by the National Centre for Biology Information (NCBI), an intramural biotechnological division of the US National Library of Medicine.
Gorbunova, N. S. +4 more
core +2 more sources
Nephrology, Volume 30, Issue 7, July 2025.ABSTRACT Parvovirus B19 infection can rarely manifest with pure red cell aplasia in immunocompromised hosts. This case details a 48‐year‐old male, 11 years post kidney‐pancreas transplant who was admitted with a chronic normocytic anaemia (haemoglobin 72 g/L) after being admitted four months prior with a bleeding peptic ulcer, requiring eight units of ...
Oscar Perry +5 more
wiley +1 more source
ERYTHROPOIETIN FOR THE TREATMENT OF SUBARACHNOID HEMORRAGE: A FEASIBLE INGREDIENT FOR A SUCCESS MEDICAL RECIPE [PDF]
, 2015 Subaracnhoid hemorrage (SAH) following aneurysm bleeding accounts for 6% to 8% of all cerebrovascular accidents. Althoug an aneurysm can be effectively managed by surgery or endovascular therapy, delayed cerebral ischemia is diagnosed in a high ...
A Gorio +101 more
core +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2016 The anemia of chronic kidney disease (CKD) is a common comorbidity seen in kidney diseases. It is also associated with increased cardiovascular morbidity and mortality and diminished quality of life.
Fatma Al Raisi +4 more
doaj
Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients [PDF]
, 2017 Background. Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients.
Ambühl, Patrice M. +8 more
core
Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review [PDF]
, 2016 AIMS: Anaemia is increasingly recognized as having an independent impact upon patient outcomes in cardiac disease. The role of novel iron therapies to treat anaemia is increasing.
Anker, SD +5 more
core +1 more source